Objective-To investigate the effects of low dose sotalol on the signal averaged surface P wave in patients with paroxysmal atrial fibrillation. Design-A longitudinal within patient crossover study. Setting-Cardiac departments of a regional cardiothoracic centre and a district general hospital. Patients-Sixteen patients with documented paroxysmal atrial fibrillation. The median (range) age of the patients was 65 5 (36-70) years; 11 were men. Main outcome measures-Analysis of the signal averaged P wave recorded from patients not receiving antiarrhythmic medication and after 4-6 weeks' treatment with sotalol. P wave limits were defined automatically by a computer algorithm. Filtered P wave duration and energies contained in frequency bands from 20, 30, 40, 60, and 80 to 150 Hz of the P wave spectrum expressed as absolute values (P20, P30, etc) and as ratios of high to low frequency energy (PR20, PR30, etc) were measured. Results-No difference in P wave duration was observed between the groups studied (mean (SEM) 149 (4) without medication and 152 (3) ms with sotalol). Significant decreases in high frequency P wave energy (for example P60: 4-3 (0.4) v 3-3 (0.3),uV2.s, P = 0.003) and energy ratio (PR60: 5 6 (0.5) v 4*7 (0.6), P = 0.03) were observed during sotalol treatment. These changes were independent of heart rate.
patients not receiving antiarrhythmic medication and after 4-6 weeks' treatment with sotalol. P wave limits were defined automatically by a computer algorithm. Filtered P wave duration and energies contained in frequency bands from 20, 30, 40, 60, and 80 to 150 Hz of the P wave spectrum expressed as absolute values (P20, P30, etc) and as ratios of high to low frequency energy (PR20, PR30, etc) were measured. Results-No difference in P wave duration was observed between the groups studied (mean (SEM) 149 (4) without medication and 152 (3) ms with sotalol). Significant decreases in high frequency P wave energy (for example P60: 4-3 (0.4) v 3-3 (0.3),uV2.s, P = 0.003) and energy ratio (PR60: 5 6 (0.5) v 4*7 (0.6), P = 0.03) were observed during sotalol treatment. These changes were independent of heart rate.
Conclusions-Treatment with low dose sotalol reduces high frequency P wave energy but does not change P wave duration. These results are consistent with the class III effect of the drug and suggest that signal averaging of the surface P wave may be a useful non-invasive measure of drug induced changes in atrial electrophysiology.
(Br HeartJ' 1995; 74:636-640) Keywords: sotalol; paroxysmal atrial fibrillation; signal averaged P wave; antiarrhythmic treatment Analysis of the signal averaged P wave in patients with paroxysmal atrial fibrillation has repeatedly shown a longer P wave duration in patients with the arrhythmia compared with that in controls.1-4 Within the frequency domain a few studies have suggested that increased P wave energy is also present in patients with paroxysmal atrial fibrillation. [4] [5] [6] The exact mechanism by which these changes in the surface P wave are generated is unresolved, but it is generally assumed that they are a consequence of the changes in intraatrial conduction that have been detected at invasive electrophysiological study.7-9 We have recently observed that changes in the signal averaged P wave found in paroxysmal atrial fibrillation are not related to differences in left atrial size,'0 and others have reported a relation between intra-atrial conduction times and signal averaged P wave duration."I The apparent ability of the signal averaged P wave to reflect differences in atrial electrophysiology associated with atrial arrhythmias suggests that the technique might also detect the effects of antiarrhythmic drug treatment on atrial electrophysiology. We tested this hypothesis by performing serial signal averaged P wave recordings in patients taking no antiarrhythmic medication and during treatment with low dose sotalol.
Patients and methods

STUDY DESIGN
Consecutive patients with paroxysmal atrial fibrillation documented by either 12 lead electrocardiography or ambulatory monitoring were recruited from outpatient attendances (20) or ward admissions (one). Patients with contraindications to fi blockade (two), who were taking antiarrhythmic medication that could not be discontinued (one), or who were taking amiodarone (two) were excluded. The remaining 16 patients gave informed consent to the study which was approved by the local hospital ethical committees.
All patients had a signal averaged P wave recording either after discontinuation of all antiarrhythmic medication for at least five half lives, or before any specific treatment for paroxysmal atrial fibrillation had been started. Patients were commenced on sotalol 40 mg twice daily increasing after 1 week to 80 mg twice daily. If the 80 mg twice daily dosage caused adverse effects a dose of 40 mg twice daily was continued instead. After 4-6 weeks' treatment with sotalol all patients returned for a second signal averaged P wave recording under identical conditions and using the same signal averaging equipment and protocol as on the first occasion.
As the study design was sequential, with all patients studied initially while taking no antiarrhythmic treatment and subsequently during treatment with sotalol, we also performed paired signal averaged recordings under identical conditions, but without antiarrhythmic treatment at the time of either recording in a further eight individuals to exclude a time effect. These recordings were made between 4 and 16 weeks apart using the same signal averaging equipment as for the patients taking sotalol.
SIGNAL AVERAGED P WAVE RECORDINGS Our signal averaging and P wave analysis methodology have been previously described.'0 12 Participants were recorded supine and relaxed in a quiet room. A modified orthogonal lead system was used. Analogue signals were amplified between 4000 and 20 000 times and bandpass filtered between 1 and 300 Hz. A fourth trigger signal was derived from one of the orthogonal leads and used to align P waves during signal averaging. The latter signal was bandpass filtered with a low pass of 50 Hz and a variable high pass of between 0 and 20 Hz. Analogue data were then digitised at 1 kHz with 12 bit resolution.
Voltage threshold triggering using the R wave of the signal selected for the trigger channel was used to identify each electrocardiographic cycle. However, P waves were then aligned by template matching to an evenly spaced 15 point P wave derived templatethat is, true P wave triggered averaging. An algorithm that automatically determined the most frequently occurring P wave morphology for each participant was used to select the averaging template. P waves with morphologies that failed to match this template accurately were rejected from the signal average.
Time domain analysis Each orthogonal lead was high pass filtered at 40 Hz using a symmetrical, 30 term finite impulse response filter. The leads were then combined to produce a vector magnitude plot of the P wave according to the formula: V =X2+Y2+Z2 P wave limits were set automatically by an algorithm that identified the P wave beginning as the point at which the vector magnitude rose to greater than three standard deviations above its baseline value and the P wave end point as the point at which the vector magni- Table 1 Repeatedfrequency domain analysis of signal averaged P waves recordedfrom eight individuals between 1 and 4 months apart* tude fell to within three standard deviations of the baseline value of the minimum PR segment magnitude. These limits were used to determine the P wave duration.
Frequency domain analysis Baseline wander was removed from each lead by subtracting from each data point a ramp generated between the beginning and end of the P wave. The signal was then high pass filtered at 15 Hz. The P wave signal was placed at the beginning of an array that was zero filled to 1024 points. A double precision fast Fourier transform was performed on these data for each lead and the outputs were summed algebraically for each frequency band.
From the aforementioned analysis P wave energy was quantified by summating the energies contained in frequency bands extending from 20, 30, 40, 60, and 80 to 150 Hz. These were expressed as absolute values (P20, P30, P40, P60, and P80 respectively) and as energy ratios defined as: Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrialfibrillation P = 0-02; P60: 4-3 (0-4) v 3-3 (03)flV2.s, P = 0 003; P80: 1 9 (0 3 v 1P4 (0 2) uV2.s, P = 0 03). These reductions in absolute high frequency energy were reflected by a significant decrease in higher frequency energy ratio (PR60: 5-6 (0 5) v 4-7 (0-6), P = 0 03), (table  3, figs 1 and 2) . Not surprisingly, heart rate was also significantly lower during treatment with sotalol than when not receiving medication (70 (4) beats/min v 60 (4) beats/min, P = 0 05), but within the two groups no correlation between change in high frequency energy and change in heart rate was found, for example change in P60 v change in heart rate, r =-002).
Discussion
As far as we are aware this is the first study to examine the effects of antiarrhythmic drug treatment on the signal averaged P wave. We found that, while there were no measurable effects on P wave duration, significant decreases in high frequency energy compared with that of baseline values occurred when patients were taking low dose sotalol. The mechanism by which sotalol produced a decrease in high frequency P wave energy is not clear. In vitro investigations have shown that it prolongs action potential duration without affecting conduction velocity in atrial and ventricular tissue.'3 In humans similar class III activity has been reported in the atria,'4 15 accessory pathways,'617 and on normal and infarcted ventricle.'8 19 The lack of effect of sotalol on P wave duration demonstrated in the study is consistent with a lack of effect on conduction velocity in the atrium. Low frequency energy (which remained unaffected) may also reflect conduction velocity, as found in ventricular tissue.20 21 The significant decreases in higher frequency energy suggest a reduction in fractionation of atrial activation. Increased action potential duration could reduce fractionation by either increasing entrance block to areas of slow conduction '8 or reducing heterogeneity in repolarisation.
Our results are consistent with the effects of higher doses of sotalol on the signal averaged QRS complex.22 In a time domain analysis of ventricular late potentials in patients not given antiarrhythmic treatment and while receiving larger doses of sotalol than were used in our patients a decrease in filtered QRS duration was observed in patients in whom sotalol prevented inducible ventricular tachycardia at electrophysiological study, but QRS duration increased in those who remained inducible. If the QRS complex was divided into an initial portion, representing normal ventricular activation, and a fractionated, high frequency (late potential) terminal portion, all of the changes in QRS complex duration were due to lengthening or shortening of the high frequency terminal part of the QRS. Thus, efficacy of sotalol in the ventricle was predicted by reduction in high frequency fractionated activity on the surface electrocardiogram. Similar fractionation during right atrial activation may occur in patients with paroxysmal atrial fibrillation within the P wave rather than at its end. Our findings suggest that sotalol reduces this high frequency activity in the atria as well as in the ventricles.
The dose of sotalol used in this study was low (80-240 mg daily). The electrophysiological effects of sotalol in humans have been observed during either intravenous administration of 1-3 mg/kg of the drug or oral dosing with 160 mg or more daily. Kunze et al reported prolongation of the refractory period of accessory pathways in patients with WolffParkinson-White syndrome at oral doses of sotalol ranging from 160 to 320 mg per day'7 and lengthening of atrial action potential has been found after a single intravenous dose of 1 mg/kg-that is about 70 mg.'5 Some authors have suggested that sotalol at low doses acts predominantly as a # blocker,23 but more sophisticated analysis of ventricular repolarisation during exercise has not confirmed these findings.'9 Nevertheless, it is possible that the effects on the signal averaged P wave that we have observed might not be related to the class III effect of the drug, but to its fi blocking action, although the lack of any correlation between heart rate reduction and decrease in high frequency energy would not support this. Further study of patients taking serial drugs, including sotalol, "pure" fi blockers, and possibly class I agents is required to investigate more fully the relation between the effects of different classes of antiarrhythmic drugs and changes in the surface P wave.
Limitations of this study include its sequential design and unblinded analysis of the P wave. However, the results of repeated signal averaged P wave recordings in a small group of individuals presented in this paper do not show any trend towards a decrease in energy over time. Blinded assessment of the P wave end points is unlikely to have altered the results, as with our system these are defined entirely automatically.
Analysis of serial signal averaged P wave recordings is likely to be a useful technique for studying the effects of antiarrhythmic drugs on atrial electrophysiology. Further investigation of changes in the signal averaged P wave after treatment with other antiarrhythmic agents, the effects of which on the atria are known, may allow more detailed correlation between the characteristics of the surface P wave and changes in underlying atrial electrophysiology. Future potential applications for this technique include the non-invasive assessment of the electrophysiological properties of drugs under development and prediction of efficacy for antiarrhythmic treatment in patients with atrial arrhythmia.
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